Sera Prognostics (NASDAQ:SERA) Stock Price Down 0.5% – Here’s Why

Sera Prognostics, Inc. (NASDAQ:SERA)’s share price traded down 0.5% during mid-day trading on Wednesday . The company traded as low as $4.09 and last traded at $4.19. 82,006 shares traded hands during mid-day trading, a decline of 44% from the average session volume of 146,420 shares. The stock had previously closed at $4.21.

Sera Prognostics Stock Down 0.5 %

The stock has a market cap of $141.50 million, a PE ratio of -4.23 and a beta of 0.81. The business’s 50-day simple moving average is $6.26 and its 200-day simple moving average is $6.92.

Insider Buying and Selling

In other Sera Prognostics news, Director Joshua Phillips sold 12,710 shares of the stock in a transaction that occurred on Friday, January 10th. The stock was sold at an average price of $7.40, for a total value of $94,054.00. Following the completion of the sale, the director now owns 5 shares in the company, valued at approximately $37. This trade represents a 99.96 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, General Counsel Benjamin Jackson sold 7,912 shares of the business’s stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $6.38, for a total value of $50,478.56. Following the transaction, the general counsel now directly owns 120,561 shares in the company, valued at $769,179.18. This trade represents a 6.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 65,615 shares of company stock valued at $462,947 over the last ninety days. 15.80% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Barclays PLC increased its position in shares of Sera Prognostics by 321.6% during the third quarter. Barclays PLC now owns 39,450 shares of the company’s stock valued at $308,000 after buying an additional 30,093 shares during the period. JPMorgan Chase & Co. boosted its position in Sera Prognostics by 7,357.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 884,867 shares of the company’s stock valued at $6,902,000 after acquiring an additional 873,002 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Sera Prognostics by 8.9% during the 3rd quarter. Geode Capital Management LLC now owns 586,837 shares of the company’s stock worth $4,578,000 after acquiring an additional 47,969 shares during the period. Quest Partners LLC raised its position in shares of Sera Prognostics by 533.5% in the 3rd quarter. Quest Partners LLC now owns 6,430 shares of the company’s stock worth $50,000 after acquiring an additional 5,415 shares in the last quarter. Finally, State Street Corp lifted its stake in shares of Sera Prognostics by 8.8% in the 3rd quarter. State Street Corp now owns 425,093 shares of the company’s stock valued at $3,316,000 after purchasing an additional 34,479 shares during the period. 54.64% of the stock is currently owned by institutional investors.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.